[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Nozoe T, Oyama T, Mori E, Uramoto H, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K: Clinicopathologic significance of an immunohistochemical expression of p27 in scirrhous carcinoma of the breast. Breast Cancer; 2007;14(3):277-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic significance of an immunohistochemical expression of p27 in scirrhous carcinoma of the breast.
  • BACKGROUND: Scirrhous carcinoma has been known to have more aggressive biological behavior than other histologic subtypes of invasive ductal carcinoma of the breast.
  • The significance of expression of p27kip1, which is thought to be a tumor suppressor gene, in breast carcinoma remains controversial.
  • The aim of the current study was to clarify clinicopathologic significance of scirrhous carcinoma of the breast with special reference to p27 expression.
  • METHODS: Clinicopathologic features including immunohistochemical expression of p27 were compared between scirrhous carcinoma (n=42) and non-scirrhous invasive ductal carcinoma (papillotubular and solid-tubular carcinoma, n=63) of the breast.
  • RESULTS: The proportion of pathologic lymph node metastasis among scirrhous carcinomas was significantly higher than that among carcinomas of other histologic types (papillotubular or solid-tubular carcinomas, p=0.029).
  • The proportion of strong expression of p27 among scirrhous carcinomas was significantly lower than that among tumors of other histologic types (p<0.0001).
  • CONCLUSIONS: Biological behavior of scirrhous carcinoma was found to be aggressive.
  • The aggressiveness and poor cellular differentiation of scirrhous carcinoma of the breast might be related to low p27 expression.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690504.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


2. Hirai K, Kikuchi S, Kurita A, Ohashi S, Adachi E, Matsuoka Y, Nagata K, Watanabe M: Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach. Anticancer Res; 2006 Jan-Feb;26(1A):71-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach.
  • BACKGROUND: The aim of the present study was to examine the immunohistochemical distribution of the 47-kDa heat shock protein (HSP47) to enhance the understanding of the mechanisms involved in stromal fibrosis, which accompanies cancer infiltration in scirrhous carcinoma of the stomach.
  • Tumor tissues were obtained from ten patients with early gastric cancer (5 scirrhous carcinoma; 5 non-scirrhous carcinoma) and three patients with advanced scirrhous gastric cancer.
  • Moreover, the number of fibroblasts in scirrhous gastric cancer was significantly greater than that in non-scirrhous gastric cancer (p = 0.0004).
  • CONCLUSION: These findings indicate that fibroblasts predominantly produce stromal collagen and may play an important role in the development of stromal change in scirrhous gastric cancer.
  • Further studies are required to elucidate the significance of HSP47 in the development of new clinical approaches for treating scirrhous gastric cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. HSP47 Heat-Shock Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cell Line, Tumor. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475681.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HSP47 Heat-Shock Proteins; 0 / SERPINH1 protein, human
  •  go-up   go-down


3. Ohta T, Tsujimoto F, Nakajima Y, Fukuda M, Takag M: Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography. Breast Cancer; 2005;12(4):304-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography.
  • BACKGROUND: Although controversy exists, invasive lobular carcinoma (ILC) differs in its high frequency of microscopically positive margins after conservative therapy compared to invasive ductal carcinoma (IDC).
  • We tried to confirm whether it is possible to distinguish ILC from other invasive carcinomas by ultrasonography (US).
  • METHODS: A total of 81 histologically confirmed cases of IDC, including 26 cases of papillotubular carcinoma, 28 cases of solid-tubular carcinoma and 27 cases of scirrhous carcinoma, as well as 24 cases of ILC were selected and retrospectively studied with regard to the features of mass lesions on US examination.
  • RESULTS: The sensitivities of US for papillotubular carcinoma, solid-tubular carcinoma, scirrhous carcinoma and ILC were 88.5%, 100%, 92.6% and 91.7% respectively.
  • One group had a low frequency of malignant findings and consisted of papillotubular and solid-tubular carcinomas, and the other group had a high frequency of malignant findings and consisted of scirrhous carcinomas and ILC.
  • However, there were no statistical differences between papillotubular carcinoma and solid-tubular carcinoma or between scirrhous carcinoma and ILC with regard to the US findings.
  • CONCLUSIONS: Scirrhous carcinoma, the most common type of IDC, and ILC are difficult to distinguish by US.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / ultrasonography. Neoplasm Invasiveness / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity


Advertisement
4. Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M: Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res; 2005 Jul-Aug;25(4):2997-3001
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
  • A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma.
  • PATIENTS AND METHODS: In this study, the relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy were investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-1:DIF, 5-FU:non-DIF) for gastric scirrhous carcinoma.
  • CONCLUSION: This study indicates that S-1 may be effective even in gastric scirrhous carcinoma with a high level of DPD activity.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / enzymology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080558.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Drug Combinations; 0 / Pyridines; 0 / Recombinant Proteins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Ninomiya K, Ohi S, Tabei I, Jin S, Tachibana T, Yamashita S, Yanaga K, Hashimoto H: Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type. Hum Cell; 2007 Aug;20(3):85-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
  • A graft in nude mouse after xenotransplantation was diagnosed as scirrhous carcinoma.
  • Radioimmunoassay indicated secretion of HER-2 protein, NCC-ST-439 and CA15-3.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cell Line, Tumor. Pleural Effusion / pathology
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Female. Genes, erbB-2. Humans. Immunohistochemistry. Karyotyping. Mice. Mice, Nude. Microscopy, Electron. Neoplasm Recurrence, Local. Neoplasm Transplantation. Transplantation, Heterologous. Trastuzumab


6. Nomura M, Inoue Y, Fujita S, Sakao J, Hirota M, Souda S, Ohshima M: Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer; 2005;12(3):226-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnosis was scirrhous carcinoma, g, ly1, v0, t2, n0, ER (-), PgR (+) and stage I A.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110294.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Hirasawa H, Tsushima Y, Hirasawa S, Takei H, Taketomi-Takahasi A, Takano A, Amanuma M, Endo K: Perfusion CT of breast carcinoma: arterial perfusion of nonscirrhous carcinoma was higher than that of scirrhous carcinoma. Acad Radiol; 2007 May;14(5):547-52
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion CT of breast carcinoma: arterial perfusion of nonscirrhous carcinoma was higher than that of scirrhous carcinoma.
  • Differences in perfusion between scirrhous and nonscirrhous carcinoma were also assessed.
  • The mean perfusion of nonscirrhous carcinoma (45.8 ml/min/100 ml; n = 11) was higher than that of scirrhous carcinoma (22.7 ml/min/100 ml; n = 11; P < .001).
  • CONCLUSION: Determination of the perfusion of breast carcinoma is feasible by dynamic CT and can be performed during a routine CT study without much supplementary burden on the patient.
  • There are differences in blood flow between scirrhous and nonscirrhous breast carcinoma, and further research is needed to determine the impact of this finding.
  • [MeSH-major] Adenocarcinoma, Scirrhous / radiography. Breast Neoplasms / radiography. Neovascularization, Pathologic / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434068.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


8. Tanaka M, Sasaki K, Kamata R, Hoshino Y, Yanagihara K, Sakai R: A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol; 2009 Jan;29(2):402-13
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an attempt to identify the SFK-binding proteins selectively phosphorylated in gastric scirrhous carcinoma, we identified an uncharacterized protein, C9orf10.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Animals. Catalytic Domain / physiology. Cell Line, Tumor. Disease Models, Animal. Humans. Insulin-Like Growth Factor II / metabolism. Insulin-Like Growth Factor II / secretion. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Phosphatidylinositol 3-Kinases / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. src Homology Domains / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Biochem. 2000 Jun;33(4):279-84 [10936586.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):723-31 [18413649.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):492-5 [11100733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1543-8 [11171987.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):489-95 [11304462.001]
  • [Cites] Breast Cancer Res. 2001;3(5):323-7 [11597322.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):366-71 [11694531.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):342-7 [12239429.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):951-6 [12459733.001]
  • [Cites] Gene. 2003 Oct 30;318:149-61 [14585507.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1940-9 [14612907.001]
  • [Cites] Biochim Biophys Acta. 2003 Dec 5;1653(2):73-86 [14643926.001]
  • [Cites] J Neurochem. 2004 May;89(3):613-26 [15086518.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):470-80 [15170449.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7928-46 [15489911.001]
  • [Cites] Cancer Cells. 1991 Jan;3(1):1-7 [2025490.001]
  • [Cites] Cell. 1992 Dec 24;71(7):1081-91 [1473146.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):16-22 [7820952.001]
  • [Cites] Biochem J. 1995 Apr 1;307 ( Pt 1):225-31 [7717979.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4293-6 [7671238.001]
  • [Cites] Nature. 1997 Feb 13;385(6617):602-9 [9024658.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20389-94 [9252345.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):519-23 [9683787.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1262-70 [9891060.001]
  • [Cites] Mol Carcinog. 1999 Jan;24(1):15-24 [10029406.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48716-24 [15355996.001]
  • [Cites] Cell Mol Life Sci. 2005 Jan;62(1):36-43 [15619005.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Jul;84(7):777-86 [16998541.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):368-77 [16841086.001]
  • [Cites] Cell Signal. 2007 May;19(5):1081-92 [17275257.001]
  • [Cites] J Pharm Sci. 2007 Sep;96(9):2181-96 [17593552.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7649-60 [17785447.001]
  • [Cites] Antioxid Redox Signal. 2008 Feb;10(2):207-47 [17999631.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1480-91 [18024423.001]
  • [Cites] J Cell Biochem. 2008 May 15;104(2):657-67 [18172854.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1729-39 [18467693.001]
  • [Cites] Growth Horm IGF Res. 2008 Aug;18(4):298-306 [18269934.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2175-83 [11031201.001]
  • (PMID = 19015244.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FAM120A protein, human; 0 / RNA-Binding Proteins; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.2 / src-Family Kinases
  • [Other-IDs] NLM/ PMC2612507
  •  go-up   go-down


9. Tabei I, Nishiyama S, Yamashita S, Hashimoto H, Tachibana T, Uchida K, Ishikawa H: Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma. Hum Cell; 2008 Nov;21(4):105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of HER2-positive cell line derived from pleural effusion of human breast scirrhous carcinoma.
  • We have established a cell line derived from a pleural effusion of breast scirrhous carcinoma.
  • Enzyme and electrochemiluminescence immunoassays of tumor markers in the conditioned medium by the cell line revealed they secrete CA15-3, NCC-ST-439 and HER2 protein.
  • We believe the cell line will contribute to the therapeutic study of malignant breast cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous. Biomarkers, Tumor / analysis. Breast Neoplasms. Pleural Effusion, Malignant. Receptor, ErbB-2
  • [MeSH-minor] Animals. Antigens, Tumor-Associated, Carbohydrate / analysis. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Karyotyping. Mice. Middle Aged. Mucin-1 / analysis. Neoplasm Transplantation. Receptors, Estrogen. Receptors, Progesterone

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - SSILY (CVCL_M362) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19067762.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / ST 439 antigen, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K: A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology; 2006 Nov;131(5):1530-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
  • BACKGROUND & AIMS: Scirrhous gastric carcinoma carries the highest mortality of all gastric cancers.
  • The aim of the current study is to clarify the possibility of molecular target therapy with Ki23057 for treating scirrhous gastric cancer.
  • OCUM-2MD3 and OCUM-8 were derived from scirrhous carcinomas.
  • MKN-7, MKN-45, and MKN-74 cells were derived from nonscirrhous carcinomas.
  • Ki23057 significantly inhibited the proliferation of scirrhous cancer cells but not nonscirrhous gastric carcinoma cells.
  • Ki23057 decreased phosphorylation of K-samII/FGF-R2, extracellular signal-regulated kinase, and Akt and increased apoptosis in scirrhous cancer lines.
  • The oral Ki23057 administration significantly (P < .001) prolonged survival of mice with peritoneal dissemination following injection of OCUM-2MD3 scirrhous cancer cells.
  • CONCLUSIONS: A novel K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, appears therapeutically promising in scirrhous gastric carcinoma with K-samII amplification.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Protein Kinase Inhibitors / pharmacology. Quinolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Peritoneal Neoplasms / pathology. Phosphorylation. Receptor, ErbB-2. Signal Transduction. Transplantation, Heterologous


11. Matsui H, Nagashima A, Kawaoka T, Hiraki S, Fukuda S: [A case of giant breast cancer performed a radical excision after neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2487-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological examination of resected specimens revealed scirrhous carcinoma with invasion to pectoralis major and skin, but no cancer cell was seen on the excised margin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037464.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Ohi S, Kyoda S, Tabei I, Ninomiya K, Sugiyama K, Hashimoto H, Tachibana T, Ishikawa H: Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma. Hum Cell; 2006 Nov;19(4):126-32
Cellosaurus - a cell line knowledge resource. culture/stock collections - NABCA (CVCL_M368) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line (NABCA) derived from metastatic lymph nodes of breast scirrhous carcinoma.
  • We successfully established a breast scirrhous carcinoma cell line (designated as NABCA) derived from metastatic tumors of the lymph node.
  • This cell line is useful for studying the mechanism of lymphatic metastasis and susceptibility of anticancer drugs in human breast scirrhous cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Breast Neoplasms / pathology. Cell Culture Techniques / methods
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Division. Cell Line, Tumor. Drug Resistance, Neoplasm. Female. Humans. Karyotyping. Lymphatic Metastasis. Male. Mice. Mice, Inbred BALB C. Microscopy, Electron. Middle Aged. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257375.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Suzuki S, Ohchi T, Doi K, Ogata K, Maeda T, Kudo K, Ishihara A: [A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1615-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological findings of axillary mass revealed infiltrating ductal carcinoma of scirrhous type.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Biopsy. Female. Humans. Immunotherapy. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799924.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Matsuura S, Aishima S, Taguchi K, Asayama Y, Terashi T, Honda H, Tsuneyoshi M: 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology; 2005 Oct;47(4):382-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1.
  • AIMS: 'Scirrhous' hepatocellular carcinoma (scirrhous HCC) is extremely rare and its characteristics remain unclear.
  • We investigated the clinicopathological and immunohistochemical features of scirrhous HCC, compared with those of ordinary hepatocellular carcinoma (ordinary HCC).
  • METHODS AND RESULTS: We compared the clinicopathological and immunohistochemical features of 20 resected cases of scirrhous HCC with those of 69 resected cases of ordinary HCC.
  • Scirrhous HCC was characterized by its gross and histological findings, such as a higher proportion of contiguous multinodular type tumours, the absence of a complete fibrous capsule around the tumour, the absence of tumour necrosis and highly preserved portal tracts in the tumour.
  • The immunohistochemical results revealed a significantly higher expression of cytokeratin 7 and a significantly lower expression of hepatocyte paraffin 1 in scirrhous HCC than in ordinary HCC (P<0.0001, respectively).
  • There were no significant differences in proliferative activity and survival curves between the patients with scirrhous HCC and those with ordinary HCC.
  • CONCLUSION: Scirrhous HCC has several particular gross, histological and immunohistochemical features.
  • In particular, we would like to emphasize the greater immunohistochemical expression of cytokeratin 7 and lower expression of hepatocyte paraffin 1 in scirrhous HCC than in ordinary HCC.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Hepatocytes / metabolism. Keratins / metabolism. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178893.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


15. Suzuki M, Ishikawa H, Tanaka A, Mataga I: Anticancer drug sensitivity testing using an oxygen electrode apparatus. Hum Cell; 2010 Aug;23(3):103-12
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we developed an oxygen electrode apparatus that uses cellular metabolism as an indicator of anticancer drug sensitivity and investigated its usefulness in 29 breast cancer patients with the following histopathological classifications: papillotubular carcinoma (n= 15); solid tubular carcinoma (n= 6); and scirrhous carcinoma (n= 8).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / pathology. Antineoplastic Agents / pharmacology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology. Drug Screening Assays, Antitumor / instrumentation. Electrodes. Oxygen / analysis
  • [MeSH-minor] Animals. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Reproducibility of Results. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Human Cell © 2010 Japan Human Cell Society.
  • (PMID = 20973835.001).
  • [ISSN] 1749-0774
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; S88TT14065 / Oxygen
  •  go-up   go-down


16. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G: Spontaneous " healing" of breast cancer. Breast Cancer; 2005;12(2):140-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focally localized healing often prevents confirmation of the continuity of intraductal carcinoma.
  • (1) The proportion of breast cancer with healing was 7% (21/311). (2) In the 21 patients, the mean age was 59.2 years, and the mean diameter was 2.8 cm. (3) The histological type of the breast cancer varied: noninvasive ductal carcinoma in 2 cases, papillotubular carcinoma in 5, solid-tubular carcinoma in 8, scirrhous carcinoma in 5, invasive lobular carcinoma in 1, and Paget's disease in 1.
  • However in all cases, the histologic type of the intraductal carcinoma foci was the comedo/solid type and the nuclear grade of cancer cells was high. (4) In cases with healing, areas of healing were seen in an average of 5 (1-26) blocks, compared with intraductal carcinoma foci in 13 blocks (2-40).
  • CONCLUSION: The proportion of breast cancer cases with healing was 7% and these cases were intraductal carcinoma of the comedo/solid type, consisting of highly malignant cancer cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / therapy. Carcinoma / therapy. Neoplasm Regression, Spontaneous / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Fibrosis. Humans. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858446.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


17. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479319.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Yen YH, Wang JH, Lu SN, Chen TY, Changchien CS, Chen CH, Hung CH, Lee CM: Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol; 2006 Dec;60(3):439-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We prospectively studied 37 hepatic tumors (34 patients), with a mean size of 2.9cm and each having a central feeding artery, by CDUS/PDUS.
  • The CEUS was performed with a galactose-based microbubble contrast agent.
  • RESULTS: CEUS showed a central feeding artery with a spoke-wheel sign in 36 tumors, including 34 FNHs and 2 hepatocellular carcinomas.
  • The two hepatocellular carcinomas showed scirrhous changes histologically.
  • Scirrhous hepatocellular carcinoma should be included in the differential diagnosis for liver tumors with spoke-wheel sign detected by CEUS.
  • [MeSH-minor] Adolescent. Adult. Biopsy. Carcinoma, Hepatocellular / ultrasonography. Contrast Media. Diagnosis, Differential. Female. Humans. Liver Neoplasms / ultrasonography. Magnetic Resonance Imaging. Male. Microbubbles. Middle Aged. Polysaccharides. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916591.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


19. Takeda Y, Yoshikawa K: Contrast-enhanced dynamic MR imaging parameters and histological types of invasive ductal carcinoma of breast. Biomed Pharmacother; 2005 Apr;59(3):115-21
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced dynamic MR imaging parameters and histological types of invasive ductal carcinoma of breast.
  • The diagnosis of breast cancer has progressed owing to the improvement of both MRI equipments and MR techniques.
  • CE-MRI is expected to be more useful for diagnosis of the existence and characteristics of breast cancer than mammography and ultrasound.
  • Forty-three breast cancer patients, who underwent breast MRI examination before surgery and had histologically confirmed invasive ductal carcinomas, were included in this study.
  • In 19, seven and 17 of them, carcinomas were histologically classified as papillotubular, solid-tubular, and scirrhous type, respectively.
  • Four of 15 parameters analyzed, ENH1-2, ENH1, MSLP, and SAT3, were significantly different between papillotubular and scirrhous carcinoma.
  • The dynamic curve of papillotubular carcinoma reached a maximum in the very early phase and then decreased slowly (linear pattern), while that of scirrhous carcinoma peaked in the slightly later phase and then decreased (parabolic pattern).
  • In the differential analysis by Kruskal-Wallis test, although no significant differences were found in any morphological parameters among three histological types, spicula formation and rim enhancement tended to appear comparatively frequently in scirrhous and solid-tubular carcinoma.
  • CE-MRI might reveal the differences of growth characteristics among different histological types of breast carcinomas and provide a diagnostic method useful for estimation of the prognosis of breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795104.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, Yanagihara K, Sakai R: CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol; 2008 Jun;172(6):1729-39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma.
  • In this study, we examined whether CDCP1 is involved in the regulation of tumor progression of scirrhous gastric cancer, which is a diffusely infiltrative carcinoma with high invasion potential.
  • Expression and phosphorylation levels of CDCP1 correlated with the invasive potential of scirrhous gastric cancers.
  • Reduction of CDCP1 expression by siRNA suppressed migration, invasion, and anchorage independence without affecting the proliferation of highly invasive scirrhous gastric cancer cells.
  • Expression and phosphorylation of CDCP1 were also detected in cancer cells of surgically resected tissues of human scirrhous gastric cancer by immunohistochemical analysis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Antigens, CD / physiology. Cell Adhesion Molecules / physiology. Neoplasm Proteins / physiology. Peritoneal Neoplasms / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement. Humans. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Phosphorylation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2003 May;996:222-6 [12799299.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):149-57 [12673672.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14772-83 [14739293.001]
  • [Cites] Stem Cells. 2004;22(3):334-43 [15153610.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 [15207811.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1317-26 [1282908.001]
  • [Cites] J Mol Biol. 1993 May 20;231(2):539-45 [8510165.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):727-40 [8647901.001]
  • [Cites] Nat Struct Biol. 1997 Oct;4(10):783-8 [9334740.001]
  • [Cites] Cell. 2005 Apr 22;121(2):271-80 [15851033.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Oncogene. 2005 Aug 11;24(34):5333-43 [16007225.001]
  • [Cites] Biol Cell. 2006 Sep;98(9):547-55 [16907663.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1530-41 [17101326.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):68-78 [17591954.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7649-60 [17785447.001]
  • [Cites] Matrix Biol. 2008 Apr;27(3):201-10 [18042364.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):497-506 [10702200.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4402-8 [11466621.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):18069-76 [11886873.001]
  • [Cites] Oncogene. 2003 Mar 27;22(12):1783-94 [12660814.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12734-43 [14718544.001]
  • (PMID = 18467693.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2408431
  •  go-up   go-down


21. Iida S, Furukawa K, Yokoyama T, Yanagihara K, Iwasaki R, Noguchi T, Tsuchiya S, Sugisaki Y, Naito Z, Tajiri T: [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1697-700
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
  • We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide).
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), pT1c (2.0 cm), n (1/10), ly3, v1, ER (-), PgR (-), HER2: score 1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Capecitabine. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940394.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Tanaka M, Kamata R, Takigahira M, Yanagihara K, Sakai R: Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. Am J Pathol; 2007 Jul;171(1):68-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma.
  • We investigated the involvement of ephrin-B1 in regulating the invasiveness of scirrhous gastric cancer, which is a diffusely infiltrative carcinoma with high invasion potential.
  • Reduction of ephrin-B1 expression by short inter-fering RNA or overexpression of phosphorylation-defective mutant suppressed migration and invasion of scirrhous gastric cancer cells in vitro without affecting tumor cell proliferation and apoptosis.
  • [MeSH-major] Adenocarcinoma, Scirrhous / metabolism. Ephrin-B1 / metabolism. Neoplasm Invasiveness. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1996 Oct 24;383(6602):722-5 [8878483.001]
  • [Cites] Cancer Res. 1986 May;46(5):2416-22 [3697985.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33 [15561600.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1197-206 [16211213.001]
  • [Cites] EMBO J. 2005 Nov 2;24(21):3700-11 [16211011.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42375-82 [16236711.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):55-63 [16362052.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):936-43 [16424028.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):454-64 [16272170.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):217-23 [16773203.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):883-9 [16784989.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7532-9 [16885351.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8492-500 [16951161.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):174-9 [11557983.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jul;128(7):343-8 [12136247.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):862-9 [12209731.001]
  • [Cites] Cell. 2002 Oct 18;111(2):251-63 [12408869.001]
  • [Cites] EMBO J. 2003 Feb 17;22(4):847-58 [12574121.001]
  • [Cites] J Cell Sci. 2003 Jul 15;116(Pt 14):2823-32 [12808016.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):991-6 [14642617.001]
  • [Cites] Biochem J. 2004 Jan 15;377(Pt 2):499-507 [14535844.001]
  • [Cites] EMBO J. 2004 Mar 10;23(5):1075-88 [14988728.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] IUBMB Life. 2004 May;56(5):257-65 [15370889.001]
  • [Cites] Dev Cell. 2004 Oct;7(4):465-80 [15469835.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3726-33 [9920925.001]
  • (PMID = 17591954.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ephrin-B1
  • [Other-IDs] NLM/ PMC1941588
  •  go-up   go-down


23. Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O: [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1301-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), 2.2 cm in size, histological grade 3, positive invasion to the lymphatic and blood vessels, negative nodal status (0/11), negative ER/PgR status, and overexpression of HER 2/neu.
  • Pathological findings were as follows: invasive ductal carcinoma (scirrhous type), 1.8 cm in size, histological grade 2, positive invasion to the lymphatic and blood vessels, negative nodal status (0/5), positive ER and uncertain PgR status, and overexpression of HER 2/neu.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Tsuchiya S: Cytological characteristics of invasive lobular carcinoma of the human breast. Med Mol Morphol; 2008 Sep;41(3):121-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological characteristics of invasive lobular carcinoma of the human breast.
  • In contrast to invasive ductal carcinoma, invasive lobular carcinoma (ILC) of the breast is characterized by multiple ipsilateral occurrences and a higher incidence in the contralateral breast.
  • It is therefore necessary to examine thoroughly whether there is any other carcinoma present before any breast-conserving surgery is carried out.
  • We cytologically, histologically, and ultrastructurally investigated ILC and pure scirrhous carcinoma (PSC), a subtype of invasive ductal carcinoma, to establish cytological diagnostic criteria for the differential diagnosis of these two types of carcinoma that have high histological similarity.
  • The carcinoma showed a rosary-like configuration.
  • These findings may contribute to histological estimation of ILC in preoperative cytological diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Female. Humans. Mammary Glands, Human / cytology. Mammary Glands, Human / pathology. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807136.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


25. Chen CY, Jaw TS, Wu DC, Kuo YT, Lee CH, Huang WT, Liu GC: MDCT of giant gastric folds: differential diagnosis. AJR Am J Roentgenol; 2010 Nov;195(5):1124-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of giant gastric folds: differential diagnosis.
  • OBJECTIVE: The purpose of this study was to evaluate the efficacy of MDCT in the differentiation of diseases involving giant gastric folds and to identify the features most useful for predicting the presence of malignant gastric disease.
  • Thirty of these patients had histopathologic results showing scirrhous carcinoma; 15, large B-cell lymphoma; 14, acute gastric mucosal lesions; and five, Ménétrier disease.
  • Unenhanced transparent volume-rendered images were assessed to determine the morphologic features of the whole stomach.
  • We used exact logistic regression to identify which MDCT image features were most predictive of the presence of malignant gastric disease.
  • CONCLUSION: MDCT may be a reliable means of noninvasive diagnosis in the care of patients with endoscopically detected giant gastric folds and may be useful for differentiating benign from malignant disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gastroscopy. Humans. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies. Stomach Neoplasms / pathology. Stomach Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966317.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Perez-Pinera P, Chang Y, Deuel TF: Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle; 2007 Dec 1;6(23):2877-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, properties of different cells induced by PTN in PTN-stimulated cells are strikingly similar to properties of highly malignant cells.
  • Furthermore, transformed cells into which Ptn is introduced undergo "switches" to malignant cells of higher malignancy with properties that are strikingly similar to properties of PTN-stimulated cells.
  • These unique features of PTN support the conclusion that constitutive PTN signaling in malignant cells that inappropriately express Ptn functions as a potent tumor promoter.
  • Recently, in confirmation, Ptn targeted by the mouse mammary tumor virus (MMTV) promoter in a transgenic mouse model was found to promote breast cancers to a more aggressive breast cancer cell phenotype that morphologically closely resembles scirrhous carcinoma in human; in addition, it promoted a striking increase in tumor angiogenesis and a remarkable degree of remodeling of the micro-environment.
  • Pleiotrophin thus regulates both different normal and pathological functions; collectively, the different studies have uncovered the unique ability of a single cytokine PTN, which signals through the unique PTN/RPTPbeta/zeta signaling pathway, to induce the many properties associated with tumor promotion in the malignant cells that constitutively express Ptn and in their microenvironment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156802.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2 T32 DK007022-26; United States / NCI NIH HHS / CA / CA84400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 0 / Growth Substances; 134034-50-7 / pleiotrophin
  • [Number-of-references] 80
  •  go-up   go-down


27. Tanigawa T, Miyamoto Y, Abe M, Hasuo T, Doiguchi M, Sakamoto F: [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1515-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
  • We experienced a case of inflammatory carcinoma, which has been well controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab.
  • A 54-year-old woman was diagnosed as inflammatory carcinoma with T4d, N3c, M0 in Stage III c.
  • The lesion was diagnosed as invasive ductal carcinoma, scirrhous, ER(-), PgR(-), HER2(3+) by core needle biopsy, The skin lesion was diagnosed as dermal lymphatic carcinomatosis by skin biopsy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma / drug therapy. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Inflammation. Middle Aged. Oxonic Acid / administration & dosage. Skin Neoplasms / drug therapy. Taxoids / administration & dosage. Tegafur / administration & dosage. Trastuzumab. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755823.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 5VT6420TIG / Oxonic Acid; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


28. Chen LL, Nolan ME, Silverstein MJ, Mihm MC Jr, Sober AJ, Tanabe KK, Smith BL, Younger J, Michaelson JS: The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer; 2009 Nov 1;115(21):5071-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: : Nine prognostic factors were identified that made marked, independent contributions to breast carcinoma lethality: grade; mucinous, medullary, tubular, and scirrhous adenocarcinoma; male sex; inflammatory disease; Paget disease; and lymph node status.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19658184.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Kijima Y, Yoshinaka H, Koriyama C, Funasako Y, Natsugoe S, Aikou T: Ultrasound examination is useful for prediction of histologic type in invasive ductal carcinoma of the breast. Ultrasound Med Biol; 2008 Apr;34(4):517-24
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound examination is useful for prediction of histologic type in invasive ductal carcinoma of the breast.
  • The aim of this study was to estimate the histologic type of invasive ductal carcinoma of the breast according to the ultrasound (US) criteria and to identify the high-risk patients for lymph node metastases.
  • An acceptable preoperative diagnosis of lymph node metastasis is essential when performing the reduction of lymphadenectomy.
  • Ultrasound examination was performed in 252 patients with invasive ductal carcinoma (91 papillotubular, 54 solid-tubular and 107 scirrhous carcinoma).
  • Histology was an important risk factor for nodal metastasis, especially in scirrhous carcinoma.
  • When comparing the US classification and histology, the accuracy rate of US for papillotubular, solid-tubular and scirrhous type was 75%, 78% and 75%, respectively.
  • To predict the scirrhous carcinoma with frequent nodal metastasis, US criteria such as the larger ratio of depth-to-width, boundary echo and attenuation of the back echo was important.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Interpretation, Computer-Assisted / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Risk Factors. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045769.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Ueno S, Nakakuma T, Aramaki N, Shiozawa K, Iizuka M, Kurita A, Miyauchi K, Sengoku N, Kuranami M: [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2471-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
  • The patient was examined as scirrhous carcinoma by lacteal gland inspection and dysplastic cell by ascites cytotechnology.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Peritonitis / etiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037459.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Sekine K, Tsunoda-Shimizu H, Kikuchi M, Saida Y, Kawasaki T, Suzuki K: DCIS showing architectural distortion on the screening mammogram - comparison of mammographic and pathological findings. Breast Cancer; 2007;14(3):281-4
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with mammograms showing architectural distortion often have an invasive carcinoma with noticeable fibrosis, such as scirrhous carcinoma or invasive lobular carcinoma.
  • However, architectural distortion is also seen in some cases of ductal carcinoma in situ (DCIS).
  • Since architectural distortion is also seen in DCIS cases, we think that besides the diagnosis of malignancy, the presence or absence of infiltration should be histopathologically established before surgery.
  • [MeSH-major] Breast Neoplasms / radiography. Carcinoma, Intraductal, Noninfiltrating / radiography. Mammography / standards

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690505.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Tsuchiya S, Li F: Electron microscopic findings for diagnosis of breast lesions. Med Mol Morphol; 2005 Dec;38(4):216-24
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electron microscopic findings for diagnosis of breast lesions.
  • The myoepithelial cells of the large duct have a large process with a crablike appearance that protrudes from the cytoplasm.
  • If the nuclei of the epithelial cells of normal mammary glands and benign breast lesions are compared with those of malignant breast lesions, the latter are primarily oval or circular in shape whereas the former often show marked notches.
  • The ICL is frequently seen in breast cancers, especially scirrhous carcinoma and lobular carcinoma.
  • Invasive ductal carcinoma can be divided into three types: papillotubular carcinoma, solid-tubular carcinoma, and scirrhous carcinoma.
  • Scirrhous carcinoma can be divided into two subtypes: scirrhous carcinoma in the broader sense of the term (characterized by scirrhous invasion of the stroma by papillotubular carcinoma or solid-tubular carcinoma), and scirrhous carcinoma in the narrower sense of the term (characterized by linear or cluster-like invasion of the stroma without forming ducts).
  • Ultrastructural characteristics of scirrhous carcinoma in the narrow sense are bright cytoplasm (seen in most cells) and euchromatin (seen in all cells of this type of carcinoma).
  • In cases of papillotubular carcinoma, solid-tubular carcinoma, and scirrhous carcinoma in the broad sense, euchromatin is predominant but sporadic cells with heterochromatin are also seen.
  • Adenoid cystic carcinoma and carcinoid tumor of the breast are histological types of breast carcinoma that show characteristic features under an electron microscope.
  • Breast carcinoma shows several ultrastructural characteristics that are useful in differential diagnosis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378230.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


33. Stern AW, Velguth KE, D'Agostino J: Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus). J Zoo Wildl Med; 2010 Jun;41(2):320-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus).
  • A 17-yr-old Western Hognose snake (Heterodon nasicus) presented with a prominent midcoelomic swelling.
  • Histologically, the mass was composed of tubules of columnar to flattened neoplastic cells with an abundant stroma and moderate cellular atypia consistent with a scirrhous adenocarcinoma, likely ductal in origin, given the location of the neoplastic mass.
  • Necropsy and histopathologic examination confirmed metastasis of the previously removed adenocarcinoma to the liver, right kidney, and large intestine.
  • [MeSH-major] Adenocarcinoma / veterinary. Snakes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597225.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kusama R, Takayama F, Tsuchiya S: MRI of the breast: comparison of MRI signals and histological characteristics of the same slices. Med Mol Morphol; 2005 Dec;38(4):204-15
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of MRI with high spatial resolution and a special breast coil has contributed to more-accurate diagnosis of breast tumor, such as determination of morphologic characteristics including internal architecture of the breast lesion.
  • However, a subtype of fibroadenoma, mastopathic type, with a poorly defined border on CFT1 and carcinoma-like enhancement, is similar to cancer on MRI.
  • Scirrhous carcinomas take either of two patterns on dynamic MRI, i.e., homogeneous enhancement or thick irregular peripheral ring enhancement.
  • The latter type shows central fibrosis zones histologically.
  • Papillotubular carcinoma shows a spotted pattern on dynamic MRI.
  • Solid-tubular carcinoma shows thin peripheral enhancement on dynamic MRI and linear high signal on CFT1.
  • This finding of CFT1 corresponds to infiltration of lymph cells and fibroblast cells in the adjacent zone.
  • Invasive lobular carcinoma shows nonmass lesions and a slow gradual enhancement pattern.
  • Mucinous carcinomas show high signal intensity on T2-weighted images because of mucin and reveal gradual enhancement.
  • The ill-defined border of mucinous carcinoma on CFT1 is useful to distinguish it from FA.
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378229.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


35. Chang Y, Zuka M, Perez-Pinera P, Astudillo A, Mortimer J, Berenson JR, Deuel TF: Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A; 2007 Jun 26;104(26):10888-93
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mouse mammary tumor virus (MMTV) promoter-driven Ptn expressed in MMTV-polyoma virus middle T antigen (PyMT)-Ptn mouse breast cancers was first shown to induce rapid growth of morphologically identified foci of "scirrhous" carcinoma and to extensively remodel the microenvironment, including increased tumor angiogenesis and striking increases in mouse protocollagens Ialpha2, IValpha5, and XIalpha1, and elastin.
  • In a coculture model of equal numbers of NIH 3T3 stromal fibroblasts and MCF-7-Ptn cells, PTN secreted from MCF-7-Ptn cells was then shown to induce a more malignant MCF-7-Ptn breast cancer cell phenotype and extensive remodeling of the MCF-7-Ptn/NIH 3T3 cell microenvironment; it up-regulated expression of markers of aggressive breast cancers, including PKCdelta and matrix metalloproteinase-9 in both MCF-7-Ptn and NIH 3T3 cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 15;332(4):1146-52 [15949466.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12407-12 [16116087.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Med Mol Morphol. 2005 Dec;38(4):216-24 [16378230.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 5;343(2):653-8 [16554021.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17795-800 [17098867.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34361-8 [10567413.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6748-57 [10597283.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):38040-7 [10986280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):78-84 [12610361.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):612-21 [14744776.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1845-53 [14661062.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Cell. 1987 Mar 13;48(5):899-907 [3545499.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Dec 29;165(3):1096-103 [2610682.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):679-82 [8421705.001]
  • [Cites] J Neurobiol. 1996 Nov;31(3):283-96 [8910787.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1814-9 [9135027.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16733-6 [9201975.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 16;335(1):232-9 [16105548.001]
  • (PMID = 17578909.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084400; United States / NIDDK NIH HHS / DK / T32 DK007022; United States / NIDDK NIH HHS / DK / 2 T32 DK007022-26; United States / NCI NIH HHS / CA / R01-CA084400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 0 / Growth Substances; 134034-50-7 / pleiotrophin
  • [Other-IDs] NLM/ PMC1904160
  •  go-up   go-down


36. Ichinose Y, Kobayashi T, Fujimoto A, Uchida S, Sasaoki T, Goto K: [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2913-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Needle biopsy revealed invasive ductal carcinoma(scirrhous carcinoma)that was ER+/PgR+/ HER2-.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Nitriles / therapeutic use. Triazoles / therapeutic use


37. Shome D, Honavar SG, Vemuganti GK, Joseph J: Orbital tuberculosis manifesting with enophthalmos and causing a diagnostic dilemma. Ophthal Plast Reconstr Surg; 2006 May-Jun;22(3):219-21
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old woman with no known systemic disease was referred with a hard mass in the left orbit and enophthalmos of two months duration.
  • Differential diagnoses of metastasis from an undetected scirrhous carcinoma and sclerosing nonspecific orbital inflammatory disease were considered and a biopsy was performed.
  • Histopathology demonstrated granulomatous inflammation with fibrosis.
  • Biopsy with histopathologic and microbioloic evaluation is essential to distinguish it from other more common causes of an orbital mass with paradoxical enophthalmos such as metastatic scirrhous carcinoma and sclerosing nonspecific orbital inflammatory disease.
  • [MeSH-major] Enophthalmos / diagnosis. Orbital Diseases / diagnosis. Tuberculosis, Ocular / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714937.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / DNA, Bacterial
  •  go-up   go-down


38. Fujii T, Zen Y, Nakanuma Y: Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. Pathol Int; 2007 Jul;57(7):443-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes.
  • Scirrhous hepatocellular carcinoma (scirrhous HCC) is a rare histological subtype of HCC characterized by marked fibrosis along the sinusoid spaces.
  • Carcinogenetic processes and pathological features at earlier stages of scirrhous HCC remain unclarified.
  • In the present report two cases of minute scirrhous HCC suggesting different carcinogenesis, are described.
  • Histologically, the inner part of the tumor was well-differentiated HCC with prominent collagen fiber deposition along the sinusoids (scirrhous HCC), whereas the outer part was a high-grade dysplastic nodule.
  • At autopsy a hepatic tumor (1.2 cm in diameter) was incidentally found in the cirrhotic liver, and was histologically scirrhous HCC without dysplastic nodule elements.
  • Carcinoma cells proliferated along the cirrhotic fibrous septa and replaced regenerative nodules.
  • These two cases suggested that scirrhous HCC could occur in dysplastic nodules (the former case) and also develop de novo in cirrhotic liver (the latter case).
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587244.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


39. Nakamura Y, Aono T, Nomura M, Iwase K, Tanaka Y: [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2165-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient was a 59-year-old woman who was diagnosed with invasive scirrhous carcinoma.
  • The second patient was a 74-year-old woman who was diagnosed with invasive ductal carcinoma in 2005.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Receptor, ErbB-2 / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084819.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Matsumoto K, Yoshinouchi S, Takano Y, Kanzaki M, Maeda M, Miyoshi S, Wakita T, Teshima S: [Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer]. Gan To Kagaku Ryoho; 2010 Mar;37(3):503-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Core needle biopsy demonstrated scirrhous carcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Neoplasm Metastasis. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332692.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1525-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After pathological examination from the ulcer, she was diagnosed as breast cancer, scirrhous carcinoma.
  • The efficacy was judged as stable disease (SD).
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755825.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Wensman H, Heldin NE, Pejler G, Hellmén E: Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors. PLoS One; 2009;4(9):e7133
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, most BMP expression studies are performed on carcinomas, and not much is known about the situation in sarcomas.
  • Clones from a scirrhous carcinoma expressed much lower BMP levels.
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Eye Proteins / metabolism. Female. Mammary Neoplasms, Animal. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Neoplasms, Experimental / metabolism. Nerve Tissue Proteins / metabolism. Phenotype. Transforming Growth Factor beta / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2000 Jun;61(3):197-210 [10965996.001]
  • [Cites] J Cell Physiol. 1998 Nov;177(2):355-63 [9766532.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 20;285(3):773-81 [11453659.001]
  • [Cites] Vet Pathol. 2001 Nov;38(6):703-9 [11732805.001]
  • [Cites] Dev Biol. 2001 Nov 1;239(1):1-14 [11784015.001]
  • [Cites] Science. 2002 May 31;296(5573):1646-7 [12040180.001]
  • [Cites] J Pathol. 2005 Jul;206(3):366-76 [15892165.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):949-52 [16175182.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35704-12 [16109715.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):411-9 [16419056.001]
  • [Cites] J Cell Biochem. 2006 Jun 1;98(3):538-54 [16317727.001]
  • [Cites] Exp Eye Res. 2006 Nov;83(5):1162-70 [16879818.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):239-46 [17004110.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1584-97 [17879955.001]
  • [Cites] Vet Pathol. 2008 Nov;45(6):803-15 [18984783.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):589-600 [17165130.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1867-71 [12154118.001]
  • [Cites] Mol Ther. 2002 Oct;6(4):464-70 [12377187.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):787-823 [12466190.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):277-81 [12543773.001]
  • [Cites] J Bone Joint Surg Am. 2003 Aug;85-A(8):1544-52 [12925636.001]
  • [Cites] Vet Pathol. 2004 Mar;41(2):154-63 [15017029.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):3024-32 [14691444.001]
  • [Cites] J Orthop Sci. 2004;9(3):334-40 [15168194.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):273-80 [15186723.001]
  • [Cites] Gene Ther. 2004 Sep;11(17):1312-20 [15269709.001]
  • [Cites] Prog Growth Factor Res. 1989;1(4):267-80 [2491264.001]
  • [Cites] Endocrinology. 1991 Oct;129(4):2187-93 [1655394.001]
  • [Cites] J Comp Pathol. 1995 Nov;113(4):327-42 [8746956.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] FEBS Lett. 1998 Aug 28;434(1-2):83-7 [9738456.001]
  • [Cites] Dev Biol. 2001 Apr 15;232(2):372-87 [11401399.001]
  • (PMID = 19771160.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins; 0 / CHRDL1 protein, human; 0 / Eye Proteins; 0 / Nerve Tissue Proteins; 0 / Smad Proteins; 0 / Transforming Growth Factor beta; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2740828
  •  go-up   go-down


43. Calaf GM, Echiburú-Chau C, Zhao YL, Hei TK: BigH3 protein expression as a marker for breast cancer. Int J Mol Med; 2008 May;21(5):561-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is widely held that breast cancer originates at the premalignant stage of atypical ductal hyperplasia, progresses to the preinvasive stage of ductal carcinoma in situ, and culminates in the potentially lethal stage of invasive ductal carcinoma.
  • Tumor grade has been a highly valuable prognostic factor for breast cancer, and high-grade ductal carcinoma in situ lesions are associated with poor clinical outcome.
  • Pathological characteristics of breast tissues ranged from benign lesions to breast cancers either of lobular or ductal carcinomas in origin, and included in situ ductal carcinomas, lobular carcinomas, infiltrating ductal carcinomas, carcinomas, scirrhous carcinomas, adenocarcinomas and infiltrating colloid carcinomas.
  • Results indicated a decrease in BigH3 protein expression from benign tissues to in situ ductal carcinoma, lobular carcinoma, infiltrating ductal carcinomas, carcinomas, scirrhous carcinoma, adenocarcinomas to infiltrating colloid carcinomas.
  • We observed that the benign tissue had a 23-fold increase in BigH3 protein expression compared to the infiltrating colloid carcinoma which was the most malignant tissue analyzed.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425347.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] United States / PHS HHS / / NAG2 1637; United States / NIEHS NIH HHS / ES / P30 ES 09089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / Transforming Growth Factor beta; 148710-76-3 / betaIG-H3 protein
  •  go-up   go-down


44. Yoshida H, Yamamoto D, Kanematsu S, Tanaka K, Ah K: [A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2901-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 53-year-old woman, who was diagnosed as breast cancer with invasive chest wall, cervical lymph node metastases, multiple bone metastases and bilateral pleural effusion[invasive ductal carcinoma, scirrhous type, ER(-), PgR(+), HER2(1+)].
  • Although AI plus bisphosphonate therapy were started at hospital discharge, disease progression and fatigue appeared.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Drug Resistance, Neoplasm. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Drug Resistance, Multiple. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160266.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


45. Ohmura T, Umekita N, Ohkubo T, Tanaka S, Maeshiro T, Matsuo S, Miyamoto S, Inoue S, Kitamura M: [Local recurrence of pancreatic cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho; 2005 Feb;32(2):239-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was Stage IVb poorly-differentiated tubular adenocarcinoma, scirrhous type, pT4, PL (+), P0, H0, pN2.
  • Systemic chemotherapy was performed with a regimen of gemcitabine 1,000 mg/m2/week for 2 weeks, followed by a week rest.
  • Two years after the diagnosis of recurrence, he returned to work, and his chemotherapy is being continued as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751641.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement